Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  VIVUS, Inc.    VVUS

News SummaryMost relevantAll newsSector newsTweets

VIVUS, Inc. : Trending News: VIVUS, SunTrust Banks, SAP AG, Google Inc

share with twitter share with LinkedIn share with facebook
share via e-mail
04/19/2013 | 05:15pm CEST

NEW YORK, April 19, 2013 - cheapstocks.us, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on VIVUS, SunTrust Banks, SAP AG, Google Inc.

VIVUS, Inc.(NASDAQ:VVUS) shares gained 3.97% to $12.57. The company on April 16 announced that the U.S. Food and Drug Administration (FDA) has approved its amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia® (phentermine and topiramate extended-release) capsules CIV. The amendment, submitted in October 2012, allows Qsymia to be dispensed through certified retail pharmacies, in addition to the existing network of certified mail-order pharmacies.

Is This A Turn Around New For VVUS? Get Free Report Here http://cheapstocks.us/index-lp2-aw.php?code=VVUS (OR Just copy and paste the link)

SunTrust Banks, Inc. (NYSE:STI) shares gained 1.72% to $27.71. The company on April 19, posted first quarter net income of $340 million from $245 million last year. Earnings per share grew 37 percent to $0.63 from $0.46 a year ago. Analysts expected the company to report earnings of $0.61 per share for the quarter. Total revenue, on a fully taxable-equivalent or FTE basis, dropped 5 percent to $2.114 billion. Revenue decreased 4 percent to $2.112 billion. Analysts had consensus revenue estimate of $2.25 billion for the quarter.

What Should Be The Fair Value Of STI After The Earnings? Find Out Here http://cheapstocks.us/index-lp2-aw.php?code=STI (OR Just copy and paste the link)

SAP AG (ADR)(NYSE:SAP) shares decreased 2.08% to $76.55. The company, on April 19, announced its financial results for the first quarter ended March 31, 2013. The company had a solid start to 2013 with 23% (25% at constant currencies) growth in non-IFRS software and cloud subscription revenue. SAP achieved ?824 million in non-IFRS software and cloud subscription revenue in the first quarter.

How Should investors Trade Sap After The Earnings? Get Free Trend Analysis Here http://cheapstocks.us/index-lp2-aw.php?code=SAP (OR Just copy and paste the link)

Looking forward, the company expects fiscal 2013 non-IFRS software and cloud subscription revenue to increase in a range of 14%-20% at constant currencies (fiscal 2012: EUR5.00 billion). The fiscal 2013 non-IFRS
cloud subscription and support revenue contributing to this growth is expected to be around EUR750 million at constant currencies (fiscal 2012: EUR343 million). The Company expects fiscal 2013 non-IFRS software and
software-related service revenue to increase in a range of 11%-13% at constant currencies (fiscal 2012: EUR13.25 billion).

Google Inc(NASDAQ:GOOG) shares increased 0.79% to $772. The company, on April 18, said core Internet business grew net revenue 23 percent in the first quarter, softening the effect of a sharp decline in its Motorola mobile phone division.

Get Complete Insight About GOOG?s Earnings Here http://cheapstocks.us/index-lp2-aw.php?code=GOOG (OR Just copy and paste the link)

The company reported a first-quarter profit of $3.35 billion, or $9.94 a share, compared with a profit of $2.89 billion, or $8.75 a share, for the year-earlier period. Adjusted revenue was $11.01 billion, compared with $8.14 billion in the same quarter the previous year. Adjusted profit was $11.58 a share. Analysts on average were expecting the company to report a profit of $10.65 a share, on revenue of $11.12 billion.

About cheapstocks.us
CheapStocks.us is a subscription-based investment newsletter that provides regular coverage, analysis, and commentary on Nasdaq, Pink Sheets and OTCBB Stocks. Subscribers receive intra-day stock analysis and commentary, as well as access to our regular Special Reports, and Trading Tools.

Cheapstocks.us is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Cheapstocks.us is a wholly owned entity of a financial public relations firm. We have not been compensated by any of the companies listed in this news release.
1419 Westwood Blvd Los
Angeles, CA

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on VIVUS, INC.
08/17 VIVUS : Patent Issued for Methods of Preventing Progression to Type 2 Diabetes M..
08/10 VIVUS, INC. : Vivus Pipeline Review, Analysis and Potential Catalysts
08/03 VIVUS,INC. (NASDAQ : VVUS) Files An 8-K Results of Operations and Financial Cond..
08/03 VIVUS INC : Results of Operations and Financial Condition, Financial Statements ..
08/03 VIVUS : Reports Second Quarter 2017 Financial Results
07/07 VIVUS, INC. (NASDAQ : VVUS) Settles With Teva Pharmaceutical Industries Ltd (ADR..
07/05 VIVUS INC : Entry into a Material Definitive Agreement, Financial Statements and..
07/05 VIVUS,INC. (NASDAQ : VVUS) Files An 8-K Entry into a Material Definitive Agreeme..
07/05 VIVUS : Announces Settlement with Actavis on Qsymia(R) Patent Litigation
More news
News from SeekingAlpha
08/15 The Balloon Goes Up For Apollo And Reshape
08/03 Vivus EPS in-line, misses on revenue
07/31 Arena Announces Full Participation In Stock Offering - What Investors Should ..
07/20 Vivus Settlement Could Clue In Orexigen Investors
07/17 QUINTILES IMS : A Novel Way To Invest In Biopharma
Financials ($)
Sales 2017 71,0 M
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 1,48x
Capi. / Sales 2018 1,65x
Capitalization 105 M
Duration : Period :
VIVUS, Inc. Technical Analysis Chart | VVUS | US9285511005 | 4-Traders
Technical analysis trends VIVUS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 2,15 $
Spread / Average Target 116%
EPS Revisions
Seth H. Z. Fischer Chief Executive Officer & Director
Mark K. Oki Chief Financial & Accounting Officer
Santosh T. Varghese Chief Medical Officer
Jorge Plutzky Director
David York Norton Director
Sector and Competitors
1st jan.Capitalization (M$)
VIVUS, INC.-13.43%105
BIOGEN7.82%59 575
CSL LIMITED28.08%45 880
GRIFOLS SA24.10%16 977